Drugs / Cannabidiol
Cannabidiol
also known as
CBD · Epidiolex · GWP42003-P · GWP42003 · Epidyolex · bsCBD · CardiolRx · Broad Spectrum Cannabidiol · +23 more
Other / unclassified targets CES1, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4, NLRP3, UGT2B7 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed epilepsy, early-onset 1 milestone | |||||
| Filed | US (FDA) | — | epilepsy, early-onset | 2026-08-03 | “Submitted New Drug Application (NDA) for cannabidiol capsule formulation to broaden utilization of cannabidiol in currently approved indications and increase flexibility for patients.” jazzpharma.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (2) | US (FDA) | EPIDIOLEX | — | 2020-07-31 – 2023-10-20 | fda.gov ↗ |
| Approved | EU (EMA) | Epidyolex | — | 2019-09-19 | europa.eu ↗ |
| Approved | US (FDA) | EPIDIOLEX | — | 2018-06-25 | fda.gov ↗ |
Trials 308 · started per year
today
US approved 2018
EU approved 2019
1
2
1
1
2
2
4
3
10
14
10
11
16
20
26
38
38
19
31
25
25
2
1
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049205020512052
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 019 trials | ||||||
| Phase 0 | NCT05650697 | Sep 2026 → Dec 2027 expected | — | University of Oklahoma | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07434895 | Jul 2026 → Dec 2029 expected | substance abuse | Hannah Harris | Recruiting | No outcome recorded |
| Phase 0 | NCT04855526 | Dec 2025 → Dec 2026 expected | cannabis dependence | Hartford Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06617247 | Dec 2024 → Dec 2026 expected | burn goodship syndrome | University of Sao Paulo | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05283382 | Oct 2024 → Dec 2026 expected | anxiety | University of Connecticut | Recruiting | No outcome recorded |
| Phase 0 | NCT05672342 | Jul 2024 → Oct 2025 | breast carcinoma, chemotherapy-induced neuropathy, colon carcinoma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT06692933 | Jun 2024 → Aug 2027 expected | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT06123702 | Apr → Dec 2024 | social phobia | Hartford Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05934500 | Oct 2023 → Jul 2025 | — | Foundation for Orthopaedic Research and Education | Withdrawn | No outcome recorded |
| Phase 0 | NCT05232123 | Jul 2023 → Dec 2024 | — | Castleton University | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT04883255 | May 2023 → Jun 2026 overdue | HIV infectious disease | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 0 | NCT05935891 | Feb 2023 → Apr 2024 | musculoskeletal system disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 0 | NCT05240755 | Jul 2022 → Jun 2024 | — | Foundation for Orthopaedic Research and Education | Completed | No outcome recorded |
| Phase 0 | NCT04777643 | Jun 2022 → Apr 2023 | — | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT04878627 | Jan 2022 → Jun 2026 overdue | anorexia nervosa | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04231643 | Sep 2021 → Nov 2023 | bipolar disorder | University of California, San Diego | Terminated | No outcome recorded |
| Phase 0 | NCT04731779 | Aug → Nov 2021 | — | Castleton University | Completed | No outcome recorded |
| Phase 0 | NCT04205682 | Jan 2020 → Jan 2021 | alcohol dependence, alcohol withdrawal | South West Sydney Local Health District | Unknown | No outcome recorded |
| Phase 0 | NCT01180374 | Feb 2010 → Oct 2014 | — | Yale University | Completed | No outcome recorded |
| Phase 150 trials | ||||||
| Phase 1 | NCT06148038 | Sep 2026 → Aug 2030 expected | breast cancer | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 1 | NCT06129591 | Sep 2026 → Jul 2027 expected | — | University of Oklahoma | Recruiting | No outcome recorded |
| Phase 1 | NCT05067387 | Aug 2026 → Jun 2027 expected | drug-induced mental disorder, substance abuse | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 1 | NCT06222268 | Mar 2026 → Sep 2031 expected | post-traumatic stress disorder | Wayne State University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06362889 | Dec 2025 overdue | acne | Rejuva Medical Aesthetics | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07001930 | Aug 2025 → Sep 2029 expected | nicotine dependence | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT07146945 | Aug 2025 → Aug 2026 | — | Delphian Therapeutics Australia Pty, Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07027566 | Jul 2025 → May 2026 overdue | dentin sensitivity | Federal University of Pará | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06854783 | Jul → Oct 2025 | — | Tiamat Australia Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06695195 | Jun 2025 → Mar 2026 overdue | — | Brent DeGeorge | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT00916201 | Jan 2025 | schizophrenia | Central Institute of Mental Health, Mannheim | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06615284 | Jan → May 2025 | coronary artery disorder, hyperlipidemia | Indication Bioscience LLC | Completed | No outcome recorded |
| Phase 1 | NCT02492074 | Dec 2024 → Apr 2025 | substance-induced psychosis | Central Institute of Mental Health, Mannheim | Withdrawn | No outcome recorded |
| Phase 1 | NCT06578455 | Aug → Nov 2024 | — | dsm-firmenich Switzerland AG | Completed | No outcome recorded |
| Phase 1 | NCT06204003 | Feb → Nov 2024 | — | University of Regina | Completed | No outcome recorded |
| Phase 1 | NCT05742724 | Jan → Feb 2024 overdue | chronic kidney disease | McMaster University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05015439 | Apr 2023 → Dec 2026 expected | autism spectrum disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT05002114 | Jan 2023 | arthropathy | Louisiana State University Health Sciences Center Shreveport | Withdrawn | No outcome recorded |
| Phase 1 | NCT04226690 | Nov 2022 → Dec 2023 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT05445804 | Nov 2022 → Dec 2026 expected | nicotine dependence | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT05037487 | Sep 2022 → Jan 2025 | drug-induced mental disorder, substance abuse | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT05032807 | Jul → Aug 2022 | — | King's College London | Completed | No outcome recorded |
| Phase 1 | NCT05429788 | May → Nov 2022 | social phobia | Receptor Life Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05269706 | May 2022 → Feb 2023 | substance-related disorder | Yasmin Hurd | Completed | No outcome recorded |
| Phase 1 | NCT05317507 | May 2022 → Mar 2023 | — | Auburn University | Completed | No outcome recorded |
| Phase 1 | NCT05678881 | Apr 2022 → Feb 2024 | epilepsy | Receptor Life Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05049733 | Mar 2022 → Jun 2023 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT05121506 | Nov 2021 → Jan 2022 | — | Gefion Canada Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04911127 | Oct 2021 → Dec 2023 | rheumatoid arthritis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT04283019 | Aug 2021 → Jun 2024 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT05023070 | Jul 2021 → Feb 2023 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1 | NCT04741477 | Jul 2021 → Sep 2022 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT04790136 | Mar → Apr 2021 | — | SocraTec R&D GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03634189 | Mar → Sep 2021 | heart failure | Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud | Unknown | No outcome recorded |
| Phase 1 | NCT04349930 | Jan 2021 → Jul 2022 | interstitial cystitis | University of New Mexico | Withdrawn | No outcome recorded |
| Phase 1 | NCT04585841 | Dec 2020 → Aug 2021 | cancer | University of Copenhagen | Completed | No outcome recorded |
| Phase 1 | NCT04201197 | Nov 2020 → Mar 2022 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT04428203 | Aug 2020 → Aug 2021 | prostate adenocarcinoma | Zin W Myint | Completed | No outcome recorded |
| Phase 1 | NCT05646459 | May 2020 | periodontitis, chronic, adult | University of Nebraska | Withdrawn | No outcome recorded |
| Phase 1 | NCT04193631 | Dec 2019 | musculoskeletal system disorder | Pure Green | Completed | No outcome recorded |
| Phase 1 | NCT03832816 | Dec 2019 → Dec 2021 | — | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03936907 | Apr → Jul 2019 | — | One World Cannabis Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03471559 | Dec 2018 → Jun 2019 | — | Central Institute of Mental Health, Mannheim | Terminated | No outcome recorded |
| Phase 1 | NCT03164512 | Jun 2018 → Aug 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02700412 | Apr 2015 → Aug 2019 | epilepsy | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1 | NCT02695537 | Apr 2015 → Feb 2019 | epilepsy | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1 | NCT02487381 | Apr → Jul 2015 | substance-induced psychosis | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| Phase 1 | NCT02286986 | Sep 2014 → Jun 2019 | epilepsy | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT02051387 | Jan 2013 → Aug 2017 | schizophrenia | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| Phase 1 | NCT01311778 | Feb 2010 → Oct 2011 | opiate dependence | Hurd,Yasmin, Ph.D. | Completed | No outcome recorded |
| Phase 1/226 trials · 1 met primary | ||||||
| Phase 1/2 | NCT07696871 | Jun → Dec 2026 expected | major depressive disorder | University of Southern Santa Catarina | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07592390 | May → Dec 2026 expected | attention deficit-hyperactivity disorder | University of Southern Santa Catarina | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07298408 | Apr → Dec 2026 expected | diabetic polyneuropathy | Florida A&M University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07278505 | Oct 2025 → Feb 2030 expected | — | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06381180 | Sep 2025 → Dec 2030 expected | cannabis dependence, post-traumatic stress disorder | Wayne State University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06738732 | Jan 2025 → Jan 2027 expected | Dravet syndrome, Lennox-Gastaut syndrome | Alexander Rotenberg | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06099379 | Jun 2024 → Jul 2026 overdue | cannabis dependence, thrombocytopenia 3 | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06381791 | May 2024 → Dec 2026 expected | osteoarthritis, rotator cuff syndrome | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05885542 | Nov 2023 → Jul 2028 expected | cannabis dependence | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03529448 | Aug 2023 → Nov 2025 | glioblastoma | Grupo Español de Investigación en Neurooncología | Completed | No outcome recorded |
| Phase 1/2 | NCT05766969 | Jun → Dec 2023 | diabetic polyneuropathy | Pure Green Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05407285 | Jul 2022 → Nov 2023 | cannabis dependence | University of Montreal Hospital Centre (CHUM) | Completed | Met primary |
| Phase 1/2 | NCT05184478 | May 2022 → Dec 2023 | Tourette syndrome | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT04642404 | Mar 2021 → Mar 2023 | dental abscess, tooth hard tissue disease | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 1/2 | NCT04731116 | Jan → Dec 2021 | COVID-19 | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT05498012 | Nov 2020 → Jan 2022 | chronic periodontitis | Palacky University | Completed | No outcome recorded |
| Phase 1/2 | NCT04238754 | Nov 2020 → Jun 2022 | drug dependence, substance withdrawal syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT03248167 | Sep 2019 → Apr 2022 | alcohol-related disorders, post-traumatic stress disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/2 | NCT03252756 | Sep 2019 → Mar 2022 | alcohol-related disorders | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/2 | NCT03805750 | Jan 2019 → Sep 2020 | essential tremor | University of California, San Diego | Completed | No outcome recorded |
| Phase 1/2 | NCT03607643 | Jan 2019 → Jun 2020 | colon carcinoma, gallbladder cancer, glioblastoma, liver cancer +3 | Leaf Vertical Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02815540 | Feb 2017 → Dec 2018 | Dravet syndrome, Lennox-Gastaut syndrome | Gillette Children's Specialty Healthcare | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02324673 | Apr 2015 → May 2016 | epilepsy | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT02332655 | Dec 2014 → Apr 2019 | Sturge-Weber syndrome | Anne Comi, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01385124 | Sep 2012 → Dec 2015 | graft versus host disease | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT01596075 | Jul 2012 → Jul 2015 | acute graft versus host disease | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 2120 trials · 4 met primary · 12 missed | ||||||
| Phase 2 | NCT03883360 | Jan → Feb 2050 | schizophrenia | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT07778810 | Sep 2026 → Jul 2028 expected | Sturge-Weber syndrome | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT07776405 | Sep 2026 → Mar 2027 expected | plantar fasciitis | University of Florida | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527338 | Jul 2026 → Feb 2031 expected | alcohol abuse | University of Colorado, Boulder | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07549256 | Jun 2026 → May 2028 expected | castration-resistant prostate carcinoma | Regionshospital Nordjylland | Recruiting | No outcome recorded |
| Phase 2 | NCT07624279 | Jun 2026 → Jul 2027 expected | headache disorder | American Society of Pain and Neuroscience, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07564245 | May 2026 → May 2029 expected | — | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07279558 | Apr 2026 → Aug 2029 expected | alcohol-related disorders | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT07570472 | Mar → May 2026 overdue | sleep disorder | KU Leuven | Recruiting | No outcome recorded |
| Phase 2 | NCT06840899 | Feb 2026 → May 2028 expected | spinal cord injury | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Show all 120 trials opens the full record — a long page | ||||||
| Phase 2/317 trials · 4 missed | ||||||
| Phase 2/3 | NCT07552974 | Jun 2026 → Feb 2027 expected | — | Associação Pan-Americana Multidisciplinar de Endocanabinologia | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06333041 | Apr 2026 → Apr 2027 expected | mucopolysaccharidosis type 3 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06514066 | Sep 2024 → Oct 2025 overdue | vascular dementia | Hospital Pengajar Universiti Putra Malaysia | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05562635 | Jul 2023 | bruxism, myofascial pain syndrome, temporomandibular joint disorder | Medical University of Silesia | Unknown | No outcome recorded |
| Phase 2/3 | NCT05020028 | Jun 2022 → Sep 2027 expected | osteoarthritis, knee | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05283161 | Apr → Aug 2022 | fibromyalgia | FG Brasil LTDA | Unknown | No outcome recorded |
| Phase 2/3 | NCT04615949 | Apr 2021 → Nov 2022 | COVID-19, cardiovascular disorder | Cardiol Therapeutics Inc. | Terminated | Missed primary Stop: Enrollment |
| Phase 2/3 | NCT04387617 | Feb 2021 → Jan 2022 | urolithiasis | Mayo Clinic | Completed | Missed primary |
| Phase 2/3 | NCT04775030 | Jan 2021 → Jan 2022 | temporomandibular joint disorder | Medical University of Silesia | Unknown | No outcome recorded |
| Phase 2/3 | NCT04672252 | Dec 2020 → Dec 2021 | neuropathy, painful | NYU Langone Health | Completed | No outcome recorded |
| Phase 2/3 | NCT04613102 | Aug 2020 → Sep 2022 | epidermolysis bullosa | Elena Pope | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04467918 | Jul 2020 → Nov 2021 | COVID-19 | University of Sao Paulo | Unknown | Missed primary |
| Phase 2/3 | NCT04504877 | Jun → Nov 2020 | COVID-19, post-traumatic stress disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT03802799 | Nov 2018 → Jun 2026 overdue | fragile X syndrome | Zynerba Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03467620 | Jul 2018 → Jul 2019 | Crohn disease | University of Illinois at Chicago | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT03310593 | Nov 2017 → Feb 2020 | bipolar depression | Hospital de Clinicas de Porto Alegre | Terminated | Missed primary |
| Phase 2/3 | NCT02283281 | May 2015 → Dec 2024 | anxiety, neuropathy, painful | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 337 trials · 5 met primary · 2 missed | ||||||
| Phase 3 | NCT07326124 | Jan 2027 → Sep 2028 expected | treatment-refractory schizophrenia | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06778564 | Oct 2026 → Feb 2028 expected | psychotic disorder | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT07148206 | Oct 2026 → May 2028 expected | opiate dependence | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07245238 | Nov 2025 → Dec 2027 expected | systemic sclerosis | Khon Kaen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07123467 | Nov 2025 → Aug 2027 expected | generalized anxiety disorder | Wayne State University | Recruiting | No outcome recorded |
| Phase 3 | NCT06940674 | Jun 2025 → Jul 2027 expected | substance-related disorder | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 3 | NCT05840822 | May 2024 → Sep 2027 expected | insomnia | Avecho Biotechnology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06099171 | Feb → Sep 2024 | — | Humanitas Clinical and Research Center | Unknown | No outcome recorded |
| Phase 3 | NCT05867849 | Oct 2023 → Dec 2029 expected | bipolar disorder | University of British Columbia | Recruiting | No outcome recorded |
| Phase 3 | NCT03825965 | May 2023 → Feb 2025 | osteoarthritis, knee | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT05288283 | Oct 2022 → Sep 2023 | epilepsy with myoclonic atonic seizures | Jazz Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04411225 | Jun 2022 → Dec 2026 expected | psychotic disorder | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 3 | NCT03549819 | Dec 2021 → Dec 2023 | agoraphobia, generalized anxiety disorder, panic disorder, social phobia | McMaster University | Unknown | No outcome recorded |
| Phase 3 | NCT05016349 | Aug → Oct 2021 | female breast carcinoma | Mahmoud Ramadan mohamed Elkazzaz | Unknown | No outcome recorded |
| Phase 3 | NCT04485104 | May 2021 → Jan 2025 | Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis | Jazz Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04729179 | Mar 2021 → Feb 2024 | fibromyalgia | Marius Henriksen | Completed | Missed primary |
| Phase 3 | NCT04611438 | Mar 2020 → Mar 2021 | Dravet syndrome, Lennox-Gastaut syndrome | Yonsei University | Unknown | No outcome recorded |
| Phase 3 | NCT04252586 | Feb 2020 → Jun 2021 | Rett syndrome | Jazz Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04271917 | Feb 2020 → Mar 2022 | — | University of Tennessee | Completed | No outcome recorded |
| Phase 3 | NCT03848832 | Jul 2019 → Jan 2021 | Rett syndrome, rifampicin-resistant tuberculosis | Jazz Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02783092 | Jan 2019 → Jul 2024 | epilepsy | Antonio Waldo Zuardi | Unknown | No outcome recorded |
| Phase 3 | NCT03421496 | Sep 2018 → May 2019 | infantile spasms | Radius Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04816994 | Jan 2018 → Dec 2025 overdue | radiculopathy | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Phase 3 | NCT02318563 | Dec 2017 → Jun 2018 | Dravet syndrome | INSYS Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT02318537 | Dec 2017 → Jun 2018 | Lennox-Gastaut syndrome | INSYS Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT02954887 | May 2017 → Jun 2019 | infantile spasms | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02953548 | Apr 2017 → May 2018 | infantile spasms | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02544750 | Aug 2016 → Jun 2021 | epilepsy, tuberous sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02544763 | Apr 2016 → Jan 2019 | epilepsy, tuberous sclerosis | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02318602 | Jan 2016 → Jun 2017 | epilepsy | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 3 | NCT02224573 | Jun 2015 → Sep 2020 | Dravet syndrome, Lennox-Gastaut syndrome | GW Research Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02224560 | Jun 2015 → May 2016 | Lennox-Gastaut syndrome | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02224690 | Apr 2015 → Mar 2016 | Lennox-Gastaut syndrome | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02224703 | Apr 2015 → Apr 2018 | Dravet syndrome | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02091375 | Mar → Nov 2015 | Dravet syndrome | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01606137 | Feb 2002 → Dec 2004 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01610713 | May 2001 → Jul 2002 | multiple sclerosis | Jazz Pharmaceuticals | Completed | Missed primary |
| Phase 415 trials · 1 missed | ||||||
| Phase 4 | NCT06924827 | Jan 2027 → Jan 2028 expected | Dravet syndrome, Lennox-Gastaut syndrome | Elizabeth Donner | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07728097 | Nov 2026 → Dec 2028 expected | Lennox-Gastaut syndrome | Jazz Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05864846 | Jun 2023 → Apr 2026 | tuberous sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT04749628 | Nov 2022 → Oct 2024 | neuropathy, painful, osteoarthritis, knee, substance-related disorder | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT05209867 | May → Dec 2022 | unexplained long-lasting fever/inflammatory syndrome | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT05324449 | Apr 2022 → Mar 2025 | anxiety, epilepsy | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT04899050 | Jul 2021 → May 2023 | — | University of South Florida | Completed | No outcome recorded |
| Phase 4 | NCT05044819 | Jul 2021 → Aug 2027 expected | Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis | Jazz Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04997954 | May 2021 → Jun 2023 | amyotrophic lateral sclerosis | Gold Coast Hospital and Health Service | Unknown | No outcome recorded |
| Phase 4 | NCT05022186 | Apr 2021 → Dec 2022 | cognitive impairment with or without cerebellar ataxia | Aristotle University Of Thessaloniki | Unknown | No outcome recorded |
| Phase 4 | NCT04603391 | Feb → Dec 2021 | — | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT04607603 | Oct 2020 → Feb 2022 | osteoarthritis, knee | Medical University of Vienna | Completed | Missed primary |
| Phase 4 | NCT04133480 | Oct 2020 → Dec 2021 | Lennox-Gastaut syndrome | Jazz Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04396730 | Apr 2020 → Mar 2022 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT03891264 | Nov 2019 → Nov 2020 | — | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Business |
| Phase not applicable17 trials · 1 met primary · 1 missed | ||||||
| — | NCT07821840 | Nov 2026 → Mar 2027 expected | generalized anxiety disorder | Associação Pan-Americana Multidisciplinar de Endocanabinologia | Not yet recruiting | No outcome recorded |
| — | NCT07471347 | Mar → Dec 2026 expected | psychiatric disorder | King's College London | Not yet recruiting | No outcome recorded |
| — | NCT07445568 | Sep 2025 | osteoarthritis, knee | Universidad del Valle de México, Campus Cuernavaca | Completed | No outcome recorded |
| — | NCT05456113 | Dec 2024 → Dec 2025 | — | Penn State University | Withdrawn | No outcome recorded Stop: Business |
| — | NCT07162454 | Nov 2024 → May 2025 | diabetic polyneuropathy | Universidad Complutense de Madrid | Completed | No outcome recorded |
| — | NCT05351905 | Nov 2022 → Dec 2025 | chronic pain syndrome | University Health Network, Toronto | Completed | No outcome recorded |
| — | NCT04831294 | Jul 2021 → May 2022 | — | Auburn University | Unknown | No outcome recorded |
| — | NCT04605393 | Jan 2021 → Jul 2023 | cannabis dependence, schizophrenia | King's College London | Completed | Missed primary |
| — | NCT04851392 | Mar 2019 → Jun 2021 | cannabis dependence | University College, London | Completed | Met primary |
| — | NCT03627117 | Aug → Dec 2018 | — | University of Basel | Completed | No outcome recorded |
| — | NCT05170217 | Nov 2017 → Jun 2019 | — | King's College London | Completed | No outcome recorded |
| — | NCT02932605 | Nov 2017 → Jan 2020 | schizophrenia | UMC Utrecht | Completed | No outcome recorded |
| — | NCT02291562 | Jul → Dec 2014 | — | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| — | NCT02112292 | Apr 2014 → Apr 2015 | — | Wageningen University | Completed | No outcome recorded |
| — | NCT02291536 | Feb → Dec 2014 | — | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| — | NCT02902081 | Feb 2013 → Mar 2017 | drug dependence | University of Chicago | Completed | No outcome recorded |
| — | NCT00397605 | Nov 2006 → Dec 2013 | bipolar disorder | University of British Columbia | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase not stated7 trials | ||||||
| — | NCT02397863 | Dec 2014 → Dec 2019 | epilepsy | Augusta University | Available | No outcome recorded |
| — | NCT02461706 | — | epilepsy | University of Florida | No longer available | No outcome recorded |
| — | NCT03196934 | — | epilepsy | MultiCare Health System Research Institute | No longer available | No outcome recorded |
| — | NCT03014440 | — | epilepsy | Eric Marsh, MD | No longer available | No outcome recorded |
| — | NCT02660255 | — | epilepsy | University of Nebraska | Approved for marketing | No outcome recorded |
| — | NCT03676049 | — | epilepsy | John | Available | No outcome recorded |
| — | NCT02556008 | — | epilepsy | University of California, Los Angeles | No longer available | No outcome recorded |
| Comparator or background therapy61 trials | ||||||
| Phase 0 | NCT06137027 Comparator | Sep 2023 → Jan 2024 | — | The University of The West Indies | Unknown | No outcome recorded |
| Phase 0 | NCT04587791 Comparator | Dec 2021 → Dec 2027 expected | chronic pain syndrome, substance-related disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05076370 Comparator | Dec 2021 → Jun 2024 | substance dependence | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT04044729 Comparator | Mar 2020 → Dec 2024 | chronic pain syndrome | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT03215940 Comparator | Feb 2018 → Dec 2024 | chronic pain syndrome | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT07462559 Comparator | Mar → Dec 2026 expected | — | Helsinki University Central Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06859710 Comparator | Nov 2025 → Sep 2027 expected | pain agnosia, substance abuse | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 1 | NCT06686914 Comparator | Jun 2025 → Dec 2028 expected | — | West Virginia University | Recruiting | No outcome recorded |
| Phase 1 | NCT06574100 Comparator | Oct 2024 → Nov 2025 overdue | — | University of Saskatchewan | Recruiting | No outcome recorded |
| Phase 1 | NCT06192589 Comparator | Feb → Sep 2024 | drug-induced liver injury | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT05490511 Comparator | Oct 2022 → Aug 2025 | chronic kidney disease, disease related to solid organ transplantation | Indiana University | Completed | No outcome recorded |
| Phase 1 | NCT04721691 Comparator | Mar 2021 → Jan 2024 | developmental and/or epileptic encephalopathy with spike-wave activation in sleep | Northwell Health | Completed | No outcome recorded |
| Phase 1 | NCT03467113 Background | Jan 2018 → Jun 2020 | Dravet syndrome, Lennox-Gastaut syndrome | Zogenix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03102918 Comparator | Feb 2016 → Aug 2017 | cannabis dependence | Mclean Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT06930703 Comparator | Apr 2025 → Feb 2027 expected | sickle cell disease | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06414473 Comparator | Jun 2024 → Dec 2026 expected | osteoarthritis, knee | University of Florida | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05132699 Comparator | Apr 2022 → Jun 2023 | post-traumatic stress disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 1/2 | NCT04760613 Comparator | Feb 2022 → Jun 2023 | radiculopathy | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/2 | NCT03904849 Comparator | Oct 2019 → Apr 2020 | alcohol-related disorders | Medical University of South Carolina | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02751359 Comparator | Jul 2016 → Jul 2017 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/2 | NCT01037322 Comparator | Jan 2010 → Sep 2012 | Crohn disease, ulcerative colitis | Meir Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT06569394 Comparator | Dec 2024 → Jun 2028 expected | cannabis dependence | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT06575751 Comparator | Dec 2024 → Jun 2028 expected | cannabis dependence | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT06629389 Comparator | Nov 2024 → Nov 2025 overdue | Parkinson disease | Laboratorio Elea Phoenix S.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT06218056 Comparator | Oct 2024 → Dec 2026 expected | nicotine dependence | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT06542445 Comparator | Aug 2024 → Aug 2026 overdue | attention deficit-hyperactivity disorder | Bazelet Nehushtan LtD. | Recruiting | No outcome recorded |
| Phase 2 | NCT05822362 Comparator | Jan 2024 → Apr 2028 expected | cognitive impairment with or without cerebellar ataxia | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT05942911 Comparator | Nov 2023 → Oct 2024 | rheumatoid arthritis | Incannex Healthcare Ltd | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06206291 Comparator | Oct 2023 → Apr 2024 | substance-related disorder | Yasmin Hurd | Completed | No outcome recorded |
| Phase 2 | NCT05823753 Comparator | Apr 2023 → Aug 2024 | social phobia | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT05632627 Comparator | Apr 2023 → Jul 2025 | traumatic brain injury | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT03787628 Comparator | May 2022 → Mar 2024 | substance-related disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT05299944 Comparator | Mar 2022 → Jul 2025 | substance-related disorder | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT04550377 Comparator | May 2021 → Mar 2026 overdue | post-traumatic stress disorder, traumatic brain injury | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT04590495 Comparator | Apr → Dec 2021 | cognitive disorder | West Virginia University | Completed | No outcome recorded |
| Phase 2 | NCT04436081 Comparator | Feb 2021 → Mar 2024 overdue | Alzheimer disease | Eastern Virginia Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT06074172 Comparator | Mar → Nov 2020 | — | Colorado State University | Completed | No outcome recorded |
| Phase 2 | NCT04197102 Comparator | Jan 2020 → May 2024 | post-traumatic stress disorder | University of Texas at Austin | Suspended | No outcome recorded |
| Phase 2 | NCT03941288 Comparator | Sep 2019 → Feb 2023 | dyspepsia, gastroparesis | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03824405 Comparator | Feb 2019 → Jan 2020 | atopic eczema | Botanix Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03635593 Comparator | Jan 2019 → Jan 2021 | chronic pain syndrome | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT02559167 Comparator | Jul 2016 → Aug 2019 | cocaine dependence, substance withdrawal syndrome | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 2 | NCT02006628 Comparator | Feb 2014 → Jan 2015 | schizophrenia | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01491490 Comparator | Oct 2011 → Oct 2012 | schizophrenia | GW Research Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT01217112 Comparator | Oct 2010 → May 2012 | hyperlipidemia, type 2 diabetes mellitus | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00309413 Comparator | Mar 2006 → Mar 2008 | schizophrenia | University of Cologne | Completed | No outcome recorded |
| Phase 2/3 | NCT07148843 Comparator | Nov 2026 → Oct 2030 expected | alcohol withdrawal, alcohol-related disorders | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05613608 Comparator | Apr 2023 → Apr 2027 expected | alcohol-related disorders | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04989413 Comparator | Oct 2022 → Feb 2025 | migraine disorder | Hospital Israelita Albert Einstein | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04423341 Comparator | May 2020 → Mar 2021 | benign essential blepharospasm | Silkiss Eye Surgery | Completed | No outcome recorded |
| Phase 3 | NCT07434973 Comparator | Dec 2026 → Dec 2029 expected | early-onset schizophrenia | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06708299 Comparator | Apr 2025 → Sep 2026 overdue | pericarditis | Cardiol Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07668856 Comparator | Feb 2025 → Nov 2027 expected | epilepsy | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT04527003 Comparator | Dec 2020 → May 2024 | endometriosis | Milton S. Hershey Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05649059 Comparator | Jul 2025 → May 2026 overdue | social phobia | Massachusetts Institute of Technology | Recruiting | No outcome recorded |
| Phase 4 | NCT04768478 Comparator | Oct 2021 → Oct 2023 | — | NYU Langone Health | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04732169 Comparator | Jul 2021 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Business |
| — | NCT07656350 Comparator | Jun 2026 → Dec 2027 expected | — | King's College London | Recruiting | No outcome recorded |
| — | NCT04059978 Comparator | May → Oct 2020 | allesthesia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT03985995 Comparator | Sep → Dec 2019 | allesthesia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT02249299 Comparator | Aug 2014 → Jun 2015 | attention deficit-hyperactivity disorder | King's College London | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 94
| Date | Issuer | Release |
|---|---|---|
| 2026-07-14 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics’ Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association cardiolrx.com ↗
The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with a high baseline disease burden. |
| 2026-06-17 | Ananda Pharma plc | Results Phase 1 MRX1 Study Delivers Strong Headline Data anandapharma.co.uk ↗
The directors announce that the Company’s Phase 1 pharmacokinetic study has now been completed, yielding highly encouraging data that confirms favourable safety and tolerability and dose selection for future clinical studies. |
| 2026-05-07 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association cardiolrx.com ↗
The peer-reviewed publication highlights clinical findings demonstrating that treatment with CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with a high baseline disease burden. |
| 2026-04-28 | Avicanna Inc | Regulatory Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update avicanna.com ↗
The Company applauds this development as a meaningful step towards advancing scientific research, improving regulatory clarity, and expanding patient access. |
| 2026-04-23 | Tilray | Regulatory Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling tilray.com ↗
With President Trump’s action to reschedule cannabis, federal policy is finally aligning with science, medicine, and most importantly, patient needs. |
| 2026-03-04 | Ananda Pharma plc | Regulatory MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis anandapharma.co.uk ↗
MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis |
| 2026-02-10 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics’ ARCHER Phase II Study Results Published in ESC Heart Failure cardiolrx.com ↗
today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. |
| 2026-01-30 | Avicanna Inc | Results Avicanna Announces Medical Cannabis Real World Evidence Results and Publication avicanna.com ↗
Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of Pain |
| 2025-12-18 | Tilray | Regulatory Tilray Accelerates U.S. Medical Cannabis Expansion After Landmark Federal Rescheduling: Launches Tilray Medical USA to Lead Nationwide Medical Cannabis Innovation and Growth tilray.com ↗
In conjunction with these regulatory changes, Tilray announced the formation of Tilray Medical USA, Inc., further strengthening its commitment to leading medical cannabis innovation and growth. |
| 2025-12-05 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting jazzpharma.com ↗
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes |
| 2025-12-01 | Cardiol Therapeutics Inc. | Results New Data from the Phase II ARCHER Trial Demonstrate CardiolRx™ Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions cardiolrx.com ↗
The data show meaningful improvements in cardiac MRI (CMR) measures of myocardial recovery in patients with acute myocarditis, a potentially fatal condition caused by viral infections, autoimmune diseases, immune checkpoint inhibitor therapy to treat cancers, and exposure to cardiotoxic substances. |
| 2025-10-13 | Tilray | Regulatory Tilray Medical Announces Expansion Plans in Panama, Strengthening Global Cannabis Leadership and Accelerating International Growth tilray.com ↗ |
| 2025-09-24 | Harmony Biosciences Management, Inc. | Results Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome harmonybiosciences.com ↗
The RECONNECT Study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate. |
| 2025-08-06 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis cardiolrx.com ↗
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo. |
| 2025-06-26 | Tilray | Results Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations tilray.com ↗ |
| 2025-06-24 | Tilray | Regulatory Tilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use tilray.com ↗
Tilray's wholly-owned subsidiary, FL Group, has become the first company in Italy to receive official authorization from the Ministero della Salute (Italian Ministry of Health) to import and distribute proprietary Tilray Medical-branded medical cannabis flower for therapeutic use. |
| 2025-03-19 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting jazzpharma.com ↗
Novel analysis of real-world Epidiolex ® (cannabidiol) treatment patterns from U.S. specialty pharmacy data found the overall probability of persistence at one year was nearly 70% (69.9%) among new patients and underscores the importance of dose optimization. |
| 2025-02-20 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science that Supports Development of its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure cardiolrx.com ↗
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death – key underlying mechanisms in heart failure |
| 2024-12-06 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting jazzpharma.com ↗
Further, the first presentation of data from the EpiCom trial, a prospective, interventional trial evaluating the impact of adjunctive Epidiolex on TSC-associated neuropsychiatric disorders (TAND), revealed improvements in behavioral symptom severity following treatment initiation. |
| 2024-11-18 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 cardiolrx.com ↗
Toronto, ON – November 18, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. |
| 2024-11-07 | Tilray | Results Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis tilray.com ↗
The study found that the cannabis extract significantly improved the rate of complete response—meaning no vomiting or use of additional medications—from 8% with placebo to 24% with THC: CBD. |
| 2024-09-09 | Tilray | Results Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms tilray.com ↗
With medical cannabis guidance and supervision, the study demonstrated improvements in pain scores, sleep quality, and overall quality of life for fibromyalgia patients. |
| 2024-09-05 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 jazzpharma.com ↗
Results showed most caregivers reported patient improvements in seizure and non-seizure outcomes since initiating Epidyolex . |
| 2024-08-22 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies jazzpharma.com ↗
No new safety signals were observed in the trial. |
| 2024-08-21 | Brains Bioceutical | Regulatory Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare brainsbioceutical.com ↗
Brains Bioceutical Corp. (BBC) has achieved a groundbreaking milestone by submitting one of the world’s first CEP (Certification of Suitability) application for its Cannabidiol (CBD) Active Pharmaceutical Ingredient (API) to the European Directorate for the Quality of Medicines & Healthcare (EDQM). |
| 2024-07-29 | Tilray | Regulatory Tilray’s Aphria RX Receives Cannabis Trading License in Germany, Significantly Expanding Commercial Growth Opportunities tilray.com ↗ |
| 2024-07-24 | Tilray | Regulatory Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal tilray.com ↗
We are proud to have received approval for our Tilray Solução Oral THC10:CBD10 product and expanding our medical cannabis offerings for patients in Portugal . |
| 2024-07-22 | Tilray | Regulatory Tilray Receives First New Cannabis Cultivation License in Germany Under New Regulations tilray.com ↗ |
| 2024-07-09 | Tilray | Results Tilray Medical Announces Scientific Study on Medical Cannabis for Patients Over Age 50 tilray.com ↗
Under medical cannabis guidance and care, the MCOPs shows correlation with improvements in pain scores, sleep and quality of life in a still growing subset of patients. |
| 2024-06-13 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis cardiolrx.com ↗ |
| 2024-05-13 | Avicanna Inc | Results Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa avicanna.com ↗
After one month of daily application of the 3% CBD Cream, 55% of patient reported improvements in wound healing while 45% displayed wound stability. |
| 2024-04-10 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting jazzpharma.com ↗
Findings showed that Epidiolex was associated with a reduction in focal seizures through 144 weeks, with an acceptable safety profile. |
| 2024-04-10 | Avicanna Inc | Results Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study avicanna.com ↗
The RWE study revealed a meaningful improvement in overall Musculoskeletal Health Questionnaire scores (p<0.001) as compared from baseline to one month. |
| 2024-04-03 | Tilray | Results Tilray Medical Announces New Scientific Publication on Age-Related Patterns of Medical Cannabis Use tilray.com ↗
The Age-related Patterns of Medical Cannabis Use study finds that older patients comprise a growing subset of medical cannabis patients. |
| 2024-03-22 | Canopy Growth Corporation | Regulatory CANOPY GROWTH CELEBRATES PASSAGE OF CANNABIS LEGALIZATION IN GERMANY canopygrowth.com ↗ |
| 2024-03-14 | Tilray | Regulatory Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal tilray.com ↗ |
| 2024-02-28 | Tilray | Regulatory Tilray Provides International Cannabis Update on Milestone German Cannabis Legalization tilray.com ↗
One fundamental change is the removal of cannabis from the list of prohibited substances in the Narcotics Act. |
| 2024-02-15 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis cardiolrx.com ↗
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) for the Company’s lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis. |
| 2024-02-13 | Avicanna Inc | Regulatory Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™ avicanna.com ↗
The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS). |
| 2024-02-05 | Orcosa Inc. | Results Orcosa Comments on Positive Results from One-Year Follow-Up Study to NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORC-144 for Acute Postoperative Pain orcosa.com ↗
today announced positive results from a one-year follow-up study to the Phase 1/2 clinical trial utilizing Orcosa’s lead product candidate, ORC-144 (cannabidiol, CBD). |
| 2024-01-30 | Avicanna Inc | Regulatory Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil avicanna.com ↗ |
| 2023-11-16 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases cardiolrx.com ↗ |
| 2023-10-10 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction cardiolrx.com ↗ |
| 2023-08-31 | MediPharm Labs Corp | Results MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients medipharmlabs.com ↗
The study data shows that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety. |
| 2023-05-25 | Tilray | Regulatory Tilray Announces European Market Expansion in Italy tilray.com ↗ |
| 2023-03-07 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure cardiolrx.com ↗
Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue |
| 2022-12-05 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies jazzpharma.com ↗
These data were presented at the 2022 American Epilepsy Society (AES) annual meeting taking place December 2–6, 2022, in Nashville, TN. |
| 2022-11-30 | Ananda Hemp, Inc. | Regulatory ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD) anandascientific.com ↗ |
| 2022-11-29 | Lexaria Bioscience Corp. | Results Lexaria's DehydraTECH-CBD™ Enhances Performance Compared to Epidiolex® in Seizure Study Program lexariabioscience.com ↗
An initial MES pilot study in animals that examined three different doses revealed that, at the lower doses of 50 mg/kg and 75 mg/kg, DehydraTECH-CBD was more efficacious than Epidiolex in reducing or eliminating seizure activity. |
| 2022-11-28 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting jazzpharma.com ↗
In addition, we are sharing long-term Phase 3 trial findings which demonstrate Epidiolex's ability to reduce tuberous sclerosis complex-related seizures over the course of three years of treatment |
| 2022-11-07 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Acute Pericarditis cardiolrx.com ↗
Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness and Significant Suppression of Key Inflammatory Markers IL-1β and IL-6. |
| 2022-10-04 | Tilray | Regulatory Tilray Medical Relaunches Cannabis Oral Solution Across Ireland tilray.com ↗
Tilray’s approved product has also recently received reimbursement approval, which gives patients cost reimbursement and ensures more eligible patients can access quality medical cannabis under Ireland’s MCAP. |
| 2022-10-03 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis cardiolrx.com ↗
The authors concluded that the API in CardiolRx™ protects cardiac function and exhibits an anti-fibrotic effect, possibly mediated by endothelial-to-mesenchymal transition (“EndoMT”). |
| 2022-09-02 | Orcosa Inc. | Results Orcosa Announces Positive Results from Phase 1/2 clinical trial utilizing ORC-144 to be Presented at the European Society for Surgery of the Shoulder and Elbow, 30th SECEC-ESSSE Congress in Dublin orcosa.com ↗ |
| 2022-08-17 | Tilray | Regulatory Tilray Medical Bolsters Market Leading Position in Europe With Market Authorization in Poland tilray.com ↗ |
| 2022-08-01 | Orcosa Inc. | Results Orcosa Congratulates Michael J. Alaia, M.D., and Researchers at NYU Langone and Baptist Health on Publication of Landmark Results from Phase 1/2 Clinical Trial Utilizing ORC-144 in The American Journal of Sports Medicine orcosa.com ↗
The findings, which were originally presented by Dr. Alaia at the Annual Meeting of the American Academy of Orthopaedic Surgeons, demonstrated that cannabidiol (CBD) administered utilizing the RITe™ Platform effectively reduces pain after shoulder surgery with no safety concerns. |
| 2022-07-15 | Orcosa Inc. | Results Orcosa Announces Positive Results from Phase 1/2 Clinical Trial Utilizing ORC-144 to be Presented at American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting orcosa.com ↗
The findings presented by Dr. Alaia at the Annual Meeting of the American Academy of Orthopaedic Surgeons demonstrated that cannabidiol (CBD) administered utilizing the RITe™ Platform effectively reduces pain after shoulder surgery with no safety concerns. |
| 2022-05-17 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis cardiolrx.com ↗ |
| 2022-05-17 | Ananda Hemp, Inc. | Regulatory University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD) anandascientific.com ↗
An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA). |
| 2022-03-25 | Orcosa Inc. | Results Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORC-144 orcosa.com ↗
The findings presented by Dr. Alaia at the Annual Meeting of the American Academy of Orthopaedic Surgeons demonstrated that cannabidiol (CBD) administered utilizing the RITe™ Platform effectively reduces pain after shoulder surgery with no safety concerns. |
| 2022-03-22 | Canopy Growth Corporation | Results CANOPY GROWTH SHINES A LIGHT ON MENSTRUAL HEALTH THROUGH CBD EFFICACY STUDY canopygrowth.com ↗
Results showed significantly reduced menstrual-related symptoms over the 6 months relative to a one-month baseline, and the higher dose was also effective in significantly reducing irritability and stress over the same period. |
| 2022-03-01 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial cardiolrx.com ↗
today announced that it has received clearance from the FDA and regulatory agencies in Brazil and Mexico to modify the inclusion criteria for the LANCER trial to allow for, amongst other things, the enrollment of vaccinated patients. |
| 2022-02-17 | Brains Bioceutical | Regulatory Brains Bioceutical’s Natural, Plant-Based Cannabidiol Receives Novel Food Validation From The United Kingdom Food Standards Agency brainsbioceutical.com ↗
Brains Bioceutical Corp. (“Brains Bio” or the “Company”) through its wholly owned subsidiary BSPG Laboratories Ltd., is pleased to announce it has received novel food validation from the UK Food Standards Agency (FSA) for its natural, plant-based CBD active pharmaceutical ingredient (API). |
| 2022-01-28 | Brains Bioceutical | Regulatory Brains Bioceutical receives official confirmation of Valid Novel Foods Application from the UK FSA brainsbioceutical.com ↗
Having successfully achieved a validated application status gives us a complete package of technical and safety data, along with toxicology reports being deemed as complete. |
| 2022-01-04 | Ananda Hemp, Inc. | Regulatory ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD) anandascientific.com ↗
This is the fourth IND approval for our investigational drug Nantheia™ product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications. |
| 2021-11-08 | Orcosa Inc. | Results Statement of Congratulations to Dr. Michael J. Alaia of NYU Langone Health Orthopedic Hospital for Best Paper Award at the 2021 Sir Robert Jones Alumni Scientific Program orcosa.com ↗
Cannabidiol Significantly Improves Early Post-Operative Pain and Patient Satisfaction after Arthroscopic Rotator Cuff Repair: A Placebo Controlled, Randomized, Double Blinded Multi-Center Trial . |
| 2021-10-26 | Tilray | Regulatory Tilray Expands Medical Cannabis Footprint in Europe tilray.com ↗
Tilray, Inc. (“ Tilray ”) (NASDAQ | TSX: TLRY), a global pioneer in medical cannabis research, cultivation, production, and distribution, today announced it has been selected by the Luxembourg Ministry of Health as a supplier of Good Manufacturing Practice (GMP) certified medical cannabis products for the country’s medical cannabis program. |
| 2021-10-25 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx™ for Acute Myocarditis cardiolrx.com ↗
it has received approval from Health Canada to proceed with the Company’s Phase II |
| 2021-10-19 | Ananda Hemp, Inc. | Regulatory ANANDA Scientific’s Liquid Structure™ Cannabidiol (CBD) to be clinically evaluated for Opioid Use Disorder. anandascientific.com ↗
An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial. |
| 2021-09-07 | Lexaria Bioscience Corp. | Results Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period lexariabioscience.com ↗
Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 7.0% (p < 0.001) in systolic pressure with DehydraTECH-CBD relative to placebo as shown below in Figure 1. |
| 2021-08-24 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx™ for Acute Myocarditis cardiolrx.com ↗ |
| 2021-07-29 | Lexaria Bioscience Corp. | Results Lexaria's DehydraTECH-CBD Lowers Blood Pressure lexariabioscience.com ↗
Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers. |
| 2021-04-12 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx™ cardiolrx.com ↗ |
| 2021-03-10 | Tilray | Regulatory Tilray® Receives Approvals to Expand and Commercialize Medical Cannabis Products in New Zealand tilray.com ↗
Tilray's product offering in New Zealand approved under the scheme is centered around its Purified CBD products. |
| 2021-02-22 | Ananda Hemp, Inc. | Regulatory Cannabidiol (CBD) and Chronic Radiculopathic Pain Syndromes anandascientific.com ↗
An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial utilizing ANANDA’s proprietary Liquid Structure™ CBD. |
| 2021-02-22 | Ananda Hemp, Inc. | Regulatory Cannabidiol (CBD) for Treatment of
Post-Traumatic Stress Disorder (PTSD) anandascientific.com ↗
An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial utilizing ANANDA’s proprietary Liquid Structure™ CBD. |
| 2021-02-04 | Tilray | Regulatory Tilray® Exports First Shipment of Medical Cannabis to Spain tilray.com ↗
The Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain . |
| 2021-02-01 | Tilray | Regulatory Tilray® Receives the First and Only Market Authorization to Offer Medical Cannabis Products in Portugal tilray.com ↗
The market authorization was issued by Infarmed, the Portuguese National Authority of Medicines and Health Products , whose rigorous process in providing such consent is internationally recognized. |
| 2020-12-22 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx™ cardiolrx.com ↗
The therapy was shown to be generally well tolerated with no serious adverse events reported in the study and 51 subjects completed all requirements of the study protocol. |
| 2020-11-23 | Canopy Growth Corporation | Results CANOPY GROWTH ANNOUNCES COMPLETION OF STUDY ON THE LONG-TERM EFFECTS OF CBD canopygrowth.com ↗
In the C. elegans model, which is recognized as a valid model for this kind of research, CBD did not demonstrate any degree of acute or life-long toxicity or related liabilities at physiological concentrations. |
| 2020-09-28 | Tilray | Results Tilray Medical Cannabis Product Shows Promise Reducing Nausea and Vomiting Caused by Chemotherapy in World First Clinical Trial tilray.com ↗
Results published in Annals of Oncology found a significant improvement in the control of chemotherapy-induced nausea and vomiting. |
| 2020-09-25 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial cardiolrx.com ↗ |
| 2020-04-01 | Cardiol Therapeutics Inc. | Results Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure cardiolrx.com ↗
The study found that Cardiol’s cannabidiol formulation significantly reduced hypertrophy and produced a dose-dependent reduction of key inflammation markers, decreases in fibrosis, and lower BNP expression. |
| 2020-03-05 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation cardiolrx.com ↗ |
| 2019-11-25 | Cardiol Therapeutics Inc. | Regulatory Cardiol Therapeutics comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency cardiolrx.com ↗
“The DEA’s descheduling of Purisys’ pharmaceutical cannabidiol clearly establishes their acknowledgement of the consistent purity and quality of Purisys’ product,” said David Elsley, President and CEO of Cardiol Therapeutics. |
| 2019-05-28 | Canopy Growth Corporation | Regulatory Canopy Growth Subsidiary and Canopy Rivers Portfolio Company Vert Mirabel Now Fully Licensed by Health Canada canopygrowth.com ↗ |
| 2018-10-01 | Tilray | Regulatory High Park Farms™ Receives Cannabis Sales License from Health Canada tilray.com ↗
High Park Farms™ Ltd., a subsidiary of Tilray, Inc. (NASDAQ: TLRY), announced today that it has received its sales license from Health Canada to sell cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). |
| 2018-09-13 | Tilray | Regulatory Tilray® Exports Bulk Supply of Medical Cannabis Flower to Germany tilray.com ↗ |
| 2018-08-01 | Tilray | Results Tilray® 2:100 Product Shows Promise in Canada’s First Pediatric Study of Mixed THC/CBD Medical Cannabis Oil for Children with Drug-Resistant Epilepsy tilray.com ↗
In the participants who reached the target treatment dose there was a statistically significant reduction in motor seizures, and an increase in seizure-free days compared to those who did not reach the target dose. |
| 2018-05-01 | Tilray | Results Tilray® Shares Preliminary Data from the Largest National Longitudinal Medical Cannabis Patient Study in Canada tilray.com ↗
Study finds significant reduction in opioid use and improvements in quality of life within first 6 months. |
| 2018-02-16 | Avicanna Inc | Regulatory Avicanna Inc. Announces its Subsidiary Has Obtained Medical Cannabis Licenses in Colombia avicanna.com ↗
Avicanna Inc. (“Avicanna“) is pleased to announce that its Colombian subsidiary Sativa Nativa S.A.S. (“Sativa Nativa“) has been issued a psychoactive cannabis Cultivation license and a cannabis Derivatives Processing and Manufacturing license (collectively the “Licenses“) by the Colombian Ministry of Justice and Ministry of Health. |
| 2017-09-07 | Tilray | Regulatory Tilray Receives License to Produce Medical Cannabis in the European Union tilray.com ↗ |
| 2017-05-04 | Tilray | Regulatory Tilray Announces Medical Cannabis Export to Cyprus tilray.com ↗
Tilray cannabinoid products have arrived and are cleared for distribution in European Union member state Cyprus after the company received necessary approvals in Canada and Cyprus to export cannabinoid formulations for patients in Cyprus. |
| 2017-02-01 | Tilray | Regulatory Tilray Announces Medical Cannabis Export to Chile tilray.com ↗
Tilray, a global leader in medical cannabis research and production, today announced that it has received necessary regulatory approvals in Canada and Chile to export medical cannabis for distribution to Chilean patients. |
All press releases naming this drug 122 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 122 releases opens the full record — a long page | ||
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 399 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cannabidiol | “acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic...” NCT04855526 ↗332“Concurrent lines of evidence suggest that targeting the endocannabinoid (eCB) system by administration of cannabidiol (CBD) could upregulate GABAergic functions and correct...” NCT06261450 ↗ “Participants assigned to this arm will receive an oral full-spectrum cannabis extract containing cannabidiol (CBD), cannabigerol (CBG), and delta-9-tetrahydrocannabinol (THC)...” NCT07839455 ↗ “The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) taking 'artisanal' (non...” NCT06924827 ↗ “GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added...” NCT02091375 ↗ “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ “Full-spectrum Cannabis sativa extract containing cannabigerol (CBG) 30 mg/mL, cannabidiol (CBD) 30 mg/mL, and tetrahydrocannabinol (THC) 3 mg/mL, administered sublingually for...” NCT07592390 ↗ “Many physically-active Americans have begun using cannabidiol (CBD) for pain relief and improved recovery time, and CBD is of particular interest due to its positive safety...” PMID 41918004 ↗ Mar 2026 “Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic...” NCT06353828 ↗ “stimulation of the endocannabinoid (eCB) system with the administration of Cannabidiol (CBD) could upregulate GABAergic function and correct inhibitory deficits presumed...” NCT06261502 ↗ “This is a preliminary study designed to assess the safety and properties of a new oral formulation containing the two most common cannabinoids used for medicinal purposes -...” NCT03936907 ↗ |
| Known as | ATL5 | “ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule).” NCT06218056 ↗ |
| Known as | AVCN583601 | “3% Cannabidiol cream (AVCN583601)” NCT04613102 ↗ |
| Known as | BRC-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06538389 ↗ |
| Known as | Broad Spectrum Cannabidiol | “Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06569394 ↗1“Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06575751 ↗ |
| Known as | Broad-Spectrum Cannabidiol (CBD) | “Broad-Spectrum Cannabidiol (CBD)” NCT07279558 ↗ |
| Known as | bsCBD | “Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used” NCT06290063 ↗2“Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06569394 ↗ “Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06575751 ↗ |
| Known as | BTX 1204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03824405 ↗ |
| Known as | BTX 1503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03573518 ↗ |
| Known as | Cannabidiol Oil | “Drug: Cannabidiol Oil” NCT06514066 ↗ |
| Known as | Cannabidiol Oral Solution | “A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms” NCT03421496 ↗ |
| Known as | CardiolRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06708299 ↗ |
| Known as | CardiolRxTM | “CardiolRxTM (cannabidiol [CBD] solution), which is known to have anti-inflammatory properties, is being investigated to treat the underlying inflammatory process and thereby...” NCT05180240 ↗ |
| Known as | CBD | “The investigators propose to study the effects of cannabidiol (CBD) on cardiac electrical function and the autonomic nervous system in children with Dravet syndrome (DS) and...” NCT02815540 ↗194“For many years, persons with MS (PwMS) have used cannabis to relax, to reduce pain and spasticity, or to improve sleep and daily functioning, despite the lack of scientific...” PMID 39114536 ↗ Jul 2024 “This study seeks to exploit bladder cannabidiol receptors as a therapeutic drug target by conducting a double-masked, placebo-controlled randomized trial evaluating the effects...” NCT04349930 ↗ “The primary purpose of this study was to evaluate the efficacy, safety, and tolerability of Cannabidiol Oral Solution (CBD) as adjunctive therapy with vigabatrin as initial...” NCT03421496 ↗ “The non-psychoactive phytocannabinoid cannabidiol (CBD) has attracted considerable attention due to its lack of abuse potential, its excellent safety profile, its unique and...” NCT03252756 ↗ “Previous research has indicated that cannabinoids including cannabidiol (CBD), delta-9 tetrahydrocannabinol (THC), and a number of other cannabinoids may hold potential for...” NCT06477406 ↗ “The purpose of this study is to assess how Cannabidiol (CBD) impacts the effectiveness of oral contraceptive (birth control) pills and if CBD changes the possible side effects...” NCT04396730 ↗ “Concurrent lines of evidence suggest that targeting the endocannabinoid (eCB) system by administration of cannabidiol (CBD) could upregulate GABAergic functions and correct...” NCT06261450 ↗ “Participants assigned to this arm will receive an oral full-spectrum cannabis extract containing cannabidiol (CBD), cannabigerol (CBG), and delta-9-tetrahydrocannabinol (THC)...” NCT07839455 ↗ “This is a multi-center study to evaluate the efficacy and safety of Cannabidiol Oral Solution (CBD) in the treatment of children aged 6 months through 36 months with a...” NCT02551731 ↗ “GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added...” NCT02091375 ↗ |
| Known as | CBD oil | “This is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications after a...” NCT05934500 ↗1“determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants” NCT04436081 ↗ |
| Known as | CBD-OS | “The aim of the study is to evaluate the effect of cannabidiol (CBD-OS®) on cognitive functions in patients aged from 2 to 18 years old diagnosed with Dravet syndrome or...” NCT04611438 ↗ |
| Known as | DAC C-052 | “DAC C-052 "Cannabidiol" / NRF 22.10 "Oily cannabidiol solution 100 mg/ml"” NCT04790136 ↗ |
| Known as | Defined CBD | “Defined CBD is a capsule composed of highly purified (\>99.9%) hemp-derived cannabidiol (CBD) and terpenes produced as a potential sleep aid for people with insomnia.” NCT05233761 ↗ |
| Known as | Epidiolex | “We performed a randomized, double-blinded, placebo-controlled study of CBD twice daily (Epidiolex escalated to 20 mg/kg/d; Jazz Pharmaceuticals, Dublin, Ireland) in patients...” PMID 37482172 ↗ Jul 202324“Epidyolex, marketed and sold in the US and Canada as Epidiolex, is currently the only marketed CBD monotherapy with US FDA and Health Canada approval and is approved for...” NCT06578455 ↗ “Patients who completed the randomized trial enrolled to receive CBD (Epidiolex® in the United States; Epidyolex® in the EU; 100 mg/mL oral solution).” PMID 34957550 ↗ Dec 2021 “peripheral blood mononuclear cells from 23 participants who received oral CBD (Epidiolex) up to 5 mg/kg twice daily for 11 days” PMID 41252210 ↗ Nov 2025 “Study intervention is 98% pure CBD. The CBD is Greenwich Biosciences, Inc.'s 100mg/mL oral solution, brand name EPIDIOLEX.” NCT03900923 ↗ “Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.” NCT04721691 ↗ “Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution” NCT05044819 ↗ “Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.” NCT04777643 ↗ “low dose cannabidiol (CBD; Epidiolex) as adjunctive therapy for idiopathic adult-onset blepharospasm (BPS)” PMID 37606606 ↗ Aug 2023 “Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL.” NCT04982029 ↗ “FDA-approved cannabinoid cannabidiol (CBD; Epidiolex)” NCT04036968 ↗ |
| Known as | Epidyolex | “Patients received plant-derived, highly purified cannabidiol medicine (Epidiolex® in the USA; Epidyolex® in the EU; 100 mg/mL oral solution) at a dose of 20 mg/kg/day from day...” PMID 32350749 ↗ Jun 20203“Patients who completed the randomized trial enrolled to receive CBD (Epidiolex® in the United States; Epidyolex® in the EU; 100 mg/mL oral solution).” PMID 34957550 ↗ Dec 2021 “a plant-derived, highly purified pharmaceutical formulation of cannabidiol (Epidiolex® [US]/Epidyolex® [EU], 100 mg/mL oral solution)” PMID 42435131 ↗ Jul 2026 “Cannabidiol Epidyolex 100 mg/ml” NCT07462559 ↗ |
| Known as | fsCBD | “Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used” NCT06290063 ↗ |
| Known as | Full-Spectrum Cannabidiol (CBD) | “Full-Spectrum Cannabidiol (CBD)” NCT07279558 ↗ |
| Known as | GLA-015 | “new CBD granules formulation (GLA-015 / Cannabidiol 1500 mg 29,7% w/w GRA BLD P)” NCT04790136 ↗ |
| Known as | GWP42003 | “The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals.” NCT02818777 ↗ |
| Known as | GWP42003-P | “A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults” NCT02224690 ↗18“A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With” NCT02286986 ↗ “A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)” NCT02544763 ↗ |
| Known as | hemp-derived CBD | “The investigators will study the harm-reducing effect of hemp-derived CBD in non-treatment-seeking emerging adults who use cannabis regularly.” NCT06569394 ↗ |
| Known as | Kanbis | “Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms” NCT06629389 ↗ |
| Known as | MediCabilis CBD oil | “Participants will be taking the active drug MediCabilis CBD oil for 6 months.” NCT04997954 ↗ |
| Known as | Nantheia ATL5 | “Investigational Product and Mode of Administration: Nantheia ATL5, which is CBD, extracted from hemp, at a 10% strength” NCT06218056 ↗ |
| Known as | NRF 22.10 | “DAC C-052 "Cannabidiol" / NRF 22.10 "Oily cannabidiol solution 100 mg/ml"” NCT04790136 ↗ |
| Known as | RLS103 | “RLS103 (cannabidiol \[CBD\] inhaled dry powder)” NCT05429788 ↗1“RLS103 (Inhaled Dry Powder Cannabidiol [CBD])” NCT05678881 ↗ |
| Known as | ZYN002 | “ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery).” NCT03802799 ↗ |
| Action | Inhibit | “CB1 antagonists such as SR141716 and cannabidiol have antipsychotic effects comparable to those of classic neuroleptic drugs.” NCT00628290 ↗ |
| Modality | Other / unclassified | “Cannabidiol (CBD), a principal phytocannabinoid constituent” PMID 33995015 ↗ Apr 2021 |
| Route | Oral | “600 mg/day, oral, capsules” NCT00309413 ↗ |
| Target | CES1 | “CBD may inhibit a number of drug-metabolizing enzymes, including carboxylesterase 1 (CES1).” NCT04603391 ↗ |